Back

Eplerenone vs irbesartan as first line therapy in obese hypertensive patients: results of the HEBRO randomized controlled trial

28 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Aldosterone and hypertension Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Panayiotis Iliakis

Hippokration General Hospital, Athens (Greece)

5 More presentations in this session

Presentation thumbnail
Impact of hyperaldosteronism in adults with hypertension: effects on long term risk of cardiovascular disease and all cause death
Mr A. Angelico-Goncalves (Vila Nova de Gaia, PT)
Abstract Slides
Presentation thumbnail
Opportunistic aldosterone testing during hypokalemia as an alternative confirmatory test for primary aldosteronism
Miss K. L (Singapore, SG)
Abstract Slides
Presentation thumbnail
Metabolic and inflammatory phenotypic divergence between primary aldosteronism and essential hypertension: a propensity score-matched cohort study
Professor T. Liu (Tianjin, CN)
Abstract Slides
Presentation thumbnail
Efficacy and safety of baxdrostat in resistant and uncontrolled hypertension: a systematic review and meta-analysis of randomised controlled trials
Ms J. Ferraz De Sousa (BR)
Presentation thumbnail
Baxdrostat for treatment of uncontrolled and resistant hypertension: a meta-analysis and systematic review
Doctor A. Bortolotto (Sao Paulo, BR)
Abstract Slides

Access the full session

Session thumbnail
Aldosterone and hypertension

The Event

Event poster

ESC Congress 2026

28 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Eplerenone versus spironolactone and outcomes in patients with heart failure: a nationwide cohort study
21 May 2022
thumbnail
Congress Presentation
Differences between non-obese and obese patients with hypertension according to gender
14 June 2024
thumbnail
Congress Presentation
Add-on treatment with zilebesiran for inadequately controlled hypertension: KARDIA-2 RCT
1 September 2025
thumbnail
Congress Presentation
Antihypertensive drugs in experimental NAFLD as the first step to the establishment of criteria for choosing appropriate treatment of hypertension in NAFLD carriers
2 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources